1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Avacta Group Plc

Avacta Group Plc

AVCT.L
Avacta Group PlcGB flagLondon Stock Exchange
73.00
GBp
- -
- -
341.93MMarket Cap
Avacta Group Plc
AVCT.L
(London Stock Exchange)

Recent

price

73.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
0.16
0.16
0.13
0.09
0.04
0.04
0.03
0.04
0.04
0.04
0.01
0.01
0.04
0.01
- -
- -
Revenue per Share
-0.15
-0.04
-0.04
-0.05
-0.04
-0.2
-0.07
-0.09
-0.13
-0.09
-0.08
-0.11
-0.14
-0.12
-0.15
-0.1
Basic EPS, GAAP
-0.23
-0.05
-0.1
-0.06
-0.04
-0.07
-0.13
-0.09
-0.09
-0.09
-0.05
-0.09
-0.07
-0.06
-0.07
-0.07
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.45
-0.38
-0.22
-0.21
-0.15
-0.32
0.56
0.46
0.35
- -
0.05
-0.03
-0.14
-0.23
-0.3
-0.33
Book Value per Share
0.11
0.14
0.19
0.03
0.3
0.18
0.36
0.26
0.14
- -
0.23
0.13
-0.02
-0.05
0.02
- -
Tangible Book Value per Share
13
15
25
32
42
50
68
68
65
111
226
250
255
273
345
400
Basic Weighted Avg Shares
2
2
3
3
2
2
2
3
3
4
2
3
10
3
- -
- -
Sales/Revenue/Turnover
-80.26
-46.01
-52.46
-69.37
-126.39
-174.3
-261.62
-291.81
-377.52
-271.23
-867.49
-988.88
-288.2
-771.76
-28,151.33
-26,053.1
Operating Margin (%)
- -
- -
- -
- -
1
3
1
2
3
2
2
2
3
1
1
1
Depreciation Expense
-2
-1
-1
-2
-1
-10
-5
-6
-9
-10
-19
-26
-37
-33
-53
-39
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-90.9
-24.17
-35.34
-56.33
-92.21
-551.08
-214.64
-232.8
-319.54
-234.85
-881.11
-894.8
-379.49
-1,166.47
-46,761.95
-34,169.91
Profit Margin (%)
1
2
4
1
12
8
21
14
6
- -
49
30
-12
-22
3
-3
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
1
4
6
1
- -
LT Debt
10
11
17
16
29
19
36
30
21
- -
62
41
21
17
9
2
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
-18.33
-32.14
-83.48
-304.57
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-44.08%
-73.32%
Free Cash Flow
33.6%
23.41%
12.11%
Net Income, GAAP
22.82%
20.25%
-26.93%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
3
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.12
2024
- -
- -
- -
- -
-0.15
2025
- -
- -
- -
- -
-0.1

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Berry Genomics Co.,Ltd (000710.SZ)
Midatech Pharma plc (MTP)
Trans Genic Inc. (2342.T)
Prestige BioPharma Limited (950210.KS)
Regulus Therapeutics Inc. (RGLS)
NewAmsterdam Pharma Company N.V. (NAMSW)
Business
Avacta Group Plc is a United Kingdom-based clinical-stage life sciences company that develops peptide drug conjugates using its proprietary pre|CISION platform to deliver potent cancer therapeutics selectively to tumors via fibroblast activation protein activation; the platform enables tumor-specific release of masked payloads including doxorubicin, exatecan and Affimer drug conjugates, reducing systemic toxicity in solid tumors such as breast cancer, head and neck cancers, gastric cancer, small cell lung cancer and soft tissue sarcomas. The company offers AVA6000, a first-generation pre|CISION peptide drug conjugate of doxorubicin in Phase 1b expansion cohorts for triple negative breast cancer, salivary gland cancer and soft tissue sarcoma; AVA6103, a second-generation conjugate of exatecan advancing to IND-enabling studies for gastric, breast, pancreatic and lung cancers with planned Phase 1 initiation in early 2026; AVA7100, a preclinical third-generation Affimer drug conjugate targeting FAP-low tumors; and additional preclinical dual-payload programs addressing resistance mechanisms. Founded in 2003 and headquartered at Scale Space, White City Imperial College Campus, 58 Wood Lane, London W12 7RZ, Avacta operates principally from the United Kingdom with revenue derived geographically from South Korea and internationally, focusing on the oncology therapeutics segment while pursuing divestment of its diagnostics subsidiary Coris Bioconcept to become a pure-play biotechnology firm. Recent developments include completion of AVA6000 Phase 1a dose escalation with favorable pharmacokinetics and efficacy signals including durable responses, entry into a strategic AI collaboration with Tempus AI for trial optimization and market expansion, ongoing commercial partnership discussions for pre|CISION assets, executive team strengthening with appointments such as David Bryant as director and Yulii Shvets as chief business officer, addition of Zeus Capital as joint broker alongside Peel Hunt and Panmure Liberum, and cash position bolstered to £17.3 million as of April 2025 following Launch Diagnostics divestment to extend runway into Q1 2026.